CC
SLDB icon

Commodore Capital’s Solid Biosciences SLDB Stock Holding History

Commodore Capital’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,825,000
Closed -$21.6M – 38
2025
Q1 		$21.6M Buy
+5,825,000
New +$24.9M 1.59% 19

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Commodore Capital's SLDB Position: Q2 2025 in Review

Commodore Capital sold out of Solid Biosciences (SLDB) in Q2 2025, closing a stake of 5,825,000 shares — an estimated $21.6M sold.

Commodore Capital first reported a position in SLDB in Q1 2025 and held it in 1 quarter. The position peaked at $21.6M in Q1 2025. 114 funds tracked by Wall St. Rank hold SLDB as of Q2 2025.

  • Commodore Capital reported no remaining Solid Biosciences position as of Q2 2025 after selling out during the quarter.
  • Commodore Capital sold 5,825,000 Solid Biosciences shares in Q2 2025, an estimated $21.6M.
  • Commodore Capital first reported a position in Solid Biosciences in Q1 2025 and held it in 1 quarter.
  • Commodore Capital's Solid Biosciences position peaked at $21.6M in Q1 2025.
  • 114 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2025.

Based on Commodore Capital's 13F filing for Q2 2025, filed 14 Aug 2025.